Myriad Genetics reported Q1 2026 revenue of $200.4 million, up 2% year-over-year, driven by growth in Cancer Care Continuum and Mental Health testing despite a decline in Prenatal Health. The company launched its Precise Molecular Residual Disease (MRD) assay and received FDA approval for the MyChoice CDx test as a companion diagnostic for ovarian cancer treatment. While reporting a GAAP net loss of $34.1 million, Myriad reaffirmed its full-year 2026 revenue guidance of $860-$880 million, expecting stronger second-half performance. The company is advancing new product launches, including an AI-enabled prostate cancer test, positioning for growth in 2027 and beyond.
Alamar Biosciences announced that its NULISA platform was prominently featured in over 140 scientific presentations at the 2026 Alzheimer's Association International Conference (AAIC) in London, highlighting its growing adoption in Alzheimer's resear...
Alamar Biosciences presented extensive data from its NULISA platform at the AAIC 2026 conference, highlighting advances in blood-based biomarkers for Alzheimer's detection and staging. The company emphasized new findings on eMTBR-Tau and BD-pTau217, ...
Holtec Nuclear Corporation has filed a registration statement with the U.S. SEC for a proposed initial public offering (IPO) of its Class A common stock, planning to list on Nasdaq under the symbol "HNUC." The offering details, including share count ...
Meta has halted a new AI feature on Instagram that generated images using public account photos without user consent, following widespread privacy and copyright concerns. The feature was automatically enabled for public profiles, sparking criticism f...
Bitcoin governance controversy has resurfaced as David Bailey accused developer Luke Dashjr of introducing a blacklist in 2014 Gentoo Bitcoin software, blocking gambling transactions. Dashjr now advocates BIP-110, aiming to restrict non-financial dat...
